Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc.
Your view on CPRX
Overview
What the company does, where it operates, and who runs it.
About Catalyst Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard John Daly
- Headquarters
- 355 Alhambra Circle, Coral Gables, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard John Daly
- Headquarters
- 355 Alhambra Circle, Coral Gables, FL, US
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies.
It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015.
Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Catalyst Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. CPRX last traded at $31.49, 17.5× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Catalyst Pharmaceuticals, Inc.. Starting points for Catalyst Pharmaceuticals, Inc.: P/E 17.5, EPS $1.81, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Catalyst Pharmaceuticals, Inc.. Catalyst Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Catalyst Pharmaceuticals, Inc.. Trailing twelve-month EPS for Catalyst Pharmaceuticals, Inc. stands at $1.81. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$31.50
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy0
- Hold3
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJun 2026 | Next QtrSep 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.48 | $0.49 | $1.95 | $2.41 |
| Low estimate | $0.44 | $0.45 | $1.83 | $2.11 |
| High estimate | $0.52 | $0.52 | $2.07 | $2.60 |
| No. of analysts | 1 | 1 | 2 | 3 |
| Year-ago EPS | $0.43 | $0.43 | $1.68 | — |
| Growth | +11.6% | +13.2% | +16.3% | — |
Revenue Estimate
| Revenue | Current QtrJun 2026 | Next QtrSep 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $155.79M | $161.73M | $635.14M | $717.90M |
| Low estimate | $151.75M | $159.75M | $628.80M | $698.65M |
| High estimate | $159.27M | $163.01M | $638.73M | $733.15M |
| No. of analysts | 3 | 3 | 2 | 4 |
| Year-ago revenue | $146.56M | $148.39M | $588.99M | — |
| Growth | +6.3% | +9.0% | +7.8% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Benzinga; as of Nov 15, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Catalyst Pharmaceuticals, Inc.. Catalyst Pharmaceuticals, Inc. has reported as a listed company since 2006. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- AMLXAmylyx Pharmaceuticals, Inc.Biotechnology$3.9B
- AXSMAxsome Therapeutics, Inc.Biotechnology$7.5B
- EXELExelixis, Inc.Biotechnology$17.3B
- MDGLMadrigal Pharmaceuticals, Inc.Biotechnology$9.9B
- TLPHTalphera, Inc.Drug Manufacturers - Specialty & Generic$47M
- VKTXViking Therapeutics, Inc.Biotechnology$3.7B
- VSTMVerastem, Inc.Biotechnology$1.0B
More Biotechnology companies
- PASGPassage Bio, Inc.NASDAQ$14M
- PBIGFParadigm Biopharmaceuticals LimitedOTC$88M
- PBLAPanbela Therapeutics, Inc.OTC$53,889
- PBLSParabilis Medicines, Inc.NASDAQ$3.5B
- PBMPsyence Biomedical Ltd.NASDAQ$59,815
- PBMWWPsyence Biomedical Ltd. WarrantNASDAQ$1,140
- PBYIPuma Biotechnology, Inc.NASDAQ$402M
- PCSAProcessa Pharmaceuticals, Inc.NASDAQ$5M
- PCVXVaxcyte, Inc.NASDAQ$10.0B
- PDSBPDS Biotechnology CorporationNASDAQ$49M
- PEPGPepGen Inc.NASDAQ$302M
- PFNDPathfinder Cell Therapy, Inc.OTC$66,716
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Catalyst Pharmaceuticals, Inc., and how their positions are changing. At a $3.85B market value, institutional positions materially move Catalyst Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Catalyst Pharmaceuticals, Inc. executives and directors. Shares of Catalyst Pharmaceuticals, Inc. have traded between $19.05 and $26.58 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Catalyst Pharmaceuticals, Inc.. Coverage tracks Catalyst Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Catalyst Pharmaceuticals, Inc.